Retatrutide and the Next Generation of GLP-1s
Retatrutide is being studied as a next-generation GLP-1, designed to activate three pathways — GLP-1, GIP, and glucagon — at once. This “triple agonist” approach could help researchers understand how to push past plateaus, support energy balance, and explore more comprehensive outcomes in metabolic research.